{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T05:05:57Z","timestamp":1784264757935,"version":"3.55.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a critical treatment for pediatric acute myeloid leukemia (AML); however, relapse after transplantation remains a major challenge. This study aimed to evaluate the prognostic value of pre-transplant measurable residual disease (MRD) detected by multiparameter flow cytometry (MFC) and high-risk (HR) fusion genes on survival after transplantation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center retrospective study included 80 newly diagnosed pediatric AML patients who underwent allo-HSCT during their first complete remission between October 2019 and October 2025. All patients were treated according to the C-HUANAN-AML 15 protocol prior to transplantation, with risk stratification and treatment decisions based on European LeukemiaNet criteria and serial MFC-MRD assessments. Cox regression models were employed for statistical analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      With a median follow-up of 34.5 months, the 3-year disease-free survival (DFS) and overall survival (OS) rates were 85.5% \u00b1 4.2% and 86.8% \u00b1 4.1%, respectively. Univariate analysis identified several risk factors for inferior survival, but multivariate analysis confirmed pre-transplant MFC-MRD positivity as an independent adverse prognostic factor for both 3-year DFS and OS (DFS: HR\u00a0=\u00a014.304, 95%CI: 1.892\u2013108.155,\n                      <jats:italic>P<\/jats:italic>\n                      =\u00a00.010; OS: HR\u00a0=\u00a015.847, 95%CI: 2.036\u2013123.328,\n                      <jats:italic>P<\/jats:italic>\n                      =\u00a00.008). Among relapsed patients, the majority harbored HR fusion genes. Given the limited number of cases with specific HR fusion genes (e.g.,\n                      <jats:italic>NUP98<\/jats:italic>\n                      rearrangements, n = 4;\n                      <jats:italic>FUS<\/jats:italic>\n                      ::\n                      <jats:italic>ERG<\/jats:italic>\n                      , n = 2), these subgroup findings are exploratory and require validation in larger cohorts.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Pre-transplant MFC-MRD positivity is an independent adverse prognostic marker for survival in pediatric AML patients following allo-HSCT. Patients harboring HR fusion genes such as\n                      <jats:italic>NUP98<\/jats:italic>\n                      rearrangements or\n                      <jats:italic>FUS<\/jats:italic>\n                      ::\n                      <jats:italic>ERG<\/jats:italic>\n                      fusions may remain at risk of relapse even after successful transplantation, although this observation is based on a limited number of cases. These findings emphasize the importance of achieving deep remission to reduce tumor burden before transplantation and provide a rationale for intensified post-transplant management strategies, including maintenance therapy, for this HR population.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1864716","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T04:24:09Z","timestamp":1784262249000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Pre-transplant measurable residual disease by flow cytometry is an independent prognostic factor in pediatric acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation"],"prefix":"10.3389","volume":"16","author":[{"given":"Shaoyang","family":"Deng","sequence":"first","affiliation":[{"name":"Department of Hematology, The Affiliated Children\u2019s Hospital of Xiangya School of Medicine, Central South University (Hunan Children\u2019s Hospital)","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"He","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Children\u2019s Hospital of Xiangya School of Medicine, Central South University (Hunan Children\u2019s Hospital)","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Children\u2019s Hospital of Xiangya School of Medicine, Central South University (Hunan Children\u2019s Hospital)","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Children\u2019s Hospital of Xiangya School of Medicine, Central South University (Hunan Children\u2019s Hospital)","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benshan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Children\u2019s Hospital of Xiangya School of Medicine, Central South University (Hunan Children\u2019s Hospital)","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-4642(22)00095-5","article-title":"Worldwide trends in population-based survival for children, adolescents, and young adults diagnosed with leukaemia, by subtype, during 2000\u201314 (CONCORD-3): analysis of individual data from 258 cancer registries in 61 countries","volume":"6","author":"Ssenyonga","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)01541-0","article-title":"Socioeconomic inequalities in cancer incidence and access to health services among children and adolescents in China: a cross-sectional study","volume":"400","author":"Ni","year":"2022","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027904","article-title":"Diagnosis and management of AML in pediatric patients: consensus recommendations from an international expert panel","volume":"147","author":"Zwaan","year":"2026","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30791","article-title":"Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials","volume":"123","author":"Alexander","year":"2017","journal-title":"Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0314-7","article-title":"Improved survival for children and young adolescents with acute myeloid leukemia: a Dutch study on incidence, survival and mortality","volume":"33","author":"Reedijk","year":"2018","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28099","article-title":"Causes of early death and treatment-related death in newly diagnosed pediatric acute myeloid leukemia: recent experiences of the Dutch Childhood Oncology Group","volume":"67","author":"Klein","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04965-x","article-title":"Allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia in first complete remission: a meta-analysis","volume":"101","author":"Masetti","year":"2022","journal-title":"Ann Hematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02685-5","article-title":"The hallmarks of hematopoietic stem cell transplantation for pediatric acute myeloid leukemia","volume":"39","author":"Rettinger","year":"2025","journal-title":"Leukemia"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18765","article-title":"Impact of measurable residual disease on outcomes of unrelated donor haematopoietic cell transplantation with post-transplant cyclophosphamide in AML in first complete remission","volume":"201","author":"Nagler","year":"2023","journal-title":"Br J Haematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281585","article-title":"Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia","volume":"108","author":"Orvain","year":"2022","journal-title":"Haematologica"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.1363","article-title":"DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant","volume":"329","author":"Dillon","year":"2023","journal-title":"JAMA"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4600","article-title":"Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis","volume":"6","author":"Short","year":"2020","journal-title":"JAMA Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013626","article-title":"2021 update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16132467","article-title":"Real-world clinical utility of targeted RNA sequencing in leukemia diagnosis and management","volume":"16","author":"Kim","year":"2024","journal-title":"Cancers"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-408336","article-title":"Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group","volume":"120","author":"Loken","year":"2012","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14523","article-title":"Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002\/01 study protocol","volume":"177","author":"Buldini","year":"2017","journal-title":"Br J Haematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11784-4","article-title":"Prognostic significance of multiparametric flow cytometry minimal residual disease at two time points after induction in pediatric acute myeloid leukemia","volume":"24","author":"Zheng","year":"2024","journal-title":"BMC Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30120759","article-title":"The clinical utility of FLT3 mutation testing in acute leukemia: a Canadian consensus","volume":"30","author":"Bergeron","year":"2023","journal-title":"Curr Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025031480","article-title":"2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party","volume":"147","author":"Cloos","year":"2026","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(10)70090-5","article-title":"Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial","volume":"11","author":"Rubnitz","year":"2010","journal-title":"Lancet Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14093","article-title":"Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia; results of the NOPHO-AML 2004 study","volume":"174","author":"Tierens","year":"2016","journal-title":"Br J Haematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19086","article-title":"Long-term follow-up of haploidentical haematopoietic stem cell transplantation in paediatric patients with high-risk acute myeloid leukaemia: report from a single centre","volume":"204","author":"Bai","year":"2023","journal-title":"Br J Haematol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014804","article-title":"Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML","volume":"139","author":"Paras","year":"2022","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.46","article-title":"Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia","volume":"30","author":"Zhou","year":"2016","journal-title":"Leukemia"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18844","article-title":"Efficacy and safety of FLAG-IDA as front-line therapy in de novo paediatric acute myeloid leukaemia population","volume":"202","author":"Doan","year":"2023","journal-title":"Br J Haematol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.06.002","article-title":"FLAG-Ida regimen as bridge therapy to allotransplantation in refractory\/relapsed acute myeloid leukemia patients","volume":"17","author":"Delia","year":"2017","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.712747","article-title":"High EVI1 expression predicts adverse outcomes in children with de novo acute myeloid leukemia","volume":"11","author":"Zheng","year":"2021","journal-title":"Front Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6005","article-title":"Clinical characteristics and prognosis analysis of patients with de novo ASXL1-mutated AML treated with the C-HUNAN-AML-15 protocol: a multicenter study by the South China Pediatric AML Collaborative Group","volume":"12","author":"Zeng","year":"2023","journal-title":"Cancer Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281653","article-title":"Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia","volume":"108","author":"Bertrums","year":"2023","journal-title":"Haematologica"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024012960","article-title":"NUP98 is rearranged in 5.0% of adult East Asian patients with AML","volume":"8","author":"Kim","year":"2024","journal-title":"Blood Adv"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.70096","article-title":"White blood cell count as a powerful prognostic marker and treatment guide in paediatric acute myeloid leukaemia with NUP98 rearrangement","volume":"207","author":"Shi","year":"2025","journal-title":"Br J Haematol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011771","article-title":"Optimized cytogenetic risk-group stratification of KMT2A-rearranged pediatric acute myeloid leukemia","volume":"8","author":"van Weelderen","year":"2024","journal-title":"Blood Adv"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-485524","article-title":"Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-M\u00fcnster AML-study group","volume":"122","author":"Coenen","year":"2013","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0273-7","article-title":"Allogeneic hematopoietic stem cell transplantation for children and adolescents with high-risk cytogenetic AML: distinctly poor outcomes of FUS-ERG-positive cases","volume":"54","author":"Tomizawa","year":"2018","journal-title":"Bone Marrow Transplant"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1864716\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T04:24:11Z","timestamp":1784262251000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1864716\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":36,"alternative-id":["10.3389\/fonc.2026.1864716"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1864716","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"article-number":"1864716"}}